Introduction

A proposed hepatitis B vaccine trial on newborn babies in Guinea-Bissau has been cancelled after accusations that the research was unethical and neocolonial, drawing worldwide attention to the ethics of vaccine studies in low-income countries.

What Happened

The trial, planned at the Bandim Health Project, aimed to enroll 14,000 newborns, with half receiving the hepatitis B vaccine at birth and the other half receiving no injection. The US Centers for Disease Control and Prevention provided $1.6 million in funding through the University of Southern Denmark, announced under the Trump administration and Health Secretary Robert F Kennedy Jr. In October, Guinean police seized a vaccine batch from the research centre, and in January the government banned child vaccine trials, effectively halting the project. Despite internal ethics clearance, no babies were ever enrolled and no vaccinations were given.

Why This Matters

Public health experts and a WHO representative argued that withholding a WHO-recommended vaccine from half the participants was unethical, particularly in a country where hepatitis B is widespread and infants face high risks of chronic infection. The debate raised questions about whether vulnerable populations in Africa are being asked to bear research risks that would not be accepted in wealthier nations. A WHO official warned that newborns could be exposed to the virus during childbirth if mothers are infected, noting that chronic hepatitis B kills up to 25% of those affected.

Key Takeaways

  • The US-funded trial was cancelled after Guinea-Bissau's government prohibited child vaccine research and seized vaccine stocks from the Bandim Health Project.
  • No babies were enrolled and no vaccinations were administered, despite internal ethics approval.
  • The World Health Organization opposed withholding a proven intervention, citing patient safety and global health equity.
  • The controversy highlights ongoing tensions in global health research, especially around vaccine trials in Africa.

Conclusion

The cancellation underscores the importance of ethical oversight in global health research, especially when vulnerable newborn populations are involved. As Guinea-Bissau moves to align its immunization schedule with WHO recommendations, the episode reminds us that vaccine policy must prioritize safety, consent, and equity above all.